Sidelining safety--the FDA's inadequate response to the IOM.
Smith
Sheila Weiss
SW
Center on Drugs and Public Policy, Department of Pharmaceutical Health Services Research, University of Maryland School of Pharmacy, Baltimore, USA.
D017277:Drug Approval / Q000331:legislation & jurisprudence / Q000379:methods; D064420:Drug-Related Side Effects and Adverse Reactions; D033161:Government Regulation; D017146:Models, Organizational; D015969:National Academies of Science, Engineering, and Medicine, U.S., Health and Medicine Division; D009936:Organizational Innovation; D011358:Product Surveillance, Postmarketing; D014481:United States; D014486:United States Food and Drug Administration / Q000458:organization & administration* / Q000592:standards